Detalles de la búsqueda
1.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Clin Infect Dis;
75(6): 975-986, 2022 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35079789
2.
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Antimicrob Agents Chemother;
66(1): e0164321, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34694877
3.
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Clin Infect Dis;
70(4): 549-556, 2020 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30918967
4.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis;
71(8): 1920-1929, 2020 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31905383
5.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet;
393(10167): 143-155, 2019 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30420123
6.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Lancet;
391(10123): 839-849, 2018 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29310899
7.
Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.
J Antimicrob Chemother;
74(8): 2365-2369, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31039247
8.
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study".
Antimicrob Agents Chemother;
67(3): e0032622, 2023 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36794938
9.
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
AIDS;
36(1): 39-48, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34534138
10.
Comparison of indocyanine green fluorescence lymphangiography and magnetic resonance lymphangiography to investigate lymphedema of the extremities.
Ann Ital Chir;
92: 452-459, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34524114
11.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS;
35(9): 1333-1342, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33730748
12.
Antiretroviral therapy and liver disorders in the OPERA® cohort.
Ther Adv Drug Saf;
11: 2042098620976953, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33343858
13.
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
J Acquir Immune Defic Syndr;
84(1): 60-65, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31977595
14.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr;
83(3): 310-318, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31834000
15.
Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA® Observational Database.
J Int AIDS Soc;
22(12): e25418, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31802641
16.
Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
Curr HIV Res;
17(4): 266-276, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31560291
17.
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
Antivir Ther;
24(6): 393-404, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31503008
18.
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Lancet HIV;
6(9): e576-e587, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31307948
19.
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Lancet Infect Dis;
19(3): 253-264, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30732940
20.
Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.
Ther Adv Drug Saf;
9(12): 675-686, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30546862